Upstream Bio Inc. (UPB)
NASDAQ: UPBHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
UPB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $252.49M
- EPS (TTM)
- -$2.88
- Dividend yield
- None
- 52-week range
- 4.50 – 33.68
- Day range
- 4.50 – 4.72
- Volume / Avg
- 908.40K / 605.35K
- Beta
- —
- Shares outstanding
- 54.77M
- Next earnings
- Nov 4, 2026
52-week range
UPB stock today
Upstream Bio (UPB) closed at $4.61 on Oct 7, up 0.44% (+$0.02), versus the S&P 500's 0.22% decline. Shares are 86.3% below their 52-week high of $33.68, set on Jan 14, 2026 and 2.4% above the 52-week low of $4.50, near the bottom of the past year's range. UPB is down 83.0% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 75.3%.
Upstream Bio has posted a net loss over the last twelve months (EPS of -$2.88), so its P/E ratio is not meaningful. Upstream Bio's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Upstream Bio
Company profileUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. E. Rand Sutherland M.D., M.P.H.
- Headquarters
- Waltham, MA
- Employees
- 75
- IPO year
- 2024
- Website
- upstreambio.com
Analyst forecast
ForecastConsensus (7 analysts)
none
Avg. price target
$31.14+575.49%
- Strong buy 1
- Buy 4
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.67
Upstream Bio peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ZNTLZentalis Pharmaceuticals Inc. | 2.55 | -4.49% | $250.21M | vs UPB |
| IMRXImmuneering Corporation Class A | 3.86 | +0.78% | $249.73M | vs UPB |
| NAUTNautilus Biotechnology Inc. | 1.96 | +10.73% | $249.42M | vs UPB |
| ACIUAC Immune SA | 2.57 | +1.98% | $255.53M | vs UPB |
| FATEFate Therapeutics Inc. | 2.15 | -6.11% | $257.61M | vs UPB |
| PALIPalisade Bio Inc. | 1.48 | -0.67% | $257.92M | vs UPB |
| STROSutro Biopharma Inc. | 14.66 | +1.45% | $243.08M | vs UPB |
| BCYCBicycle Therapeutics plc ADR | 3.73 | -1.58% | $261.07M | vs UPB |
Indexes, lists and sector
Appears in lists
Upstream Bio stock FAQ
What is Upstream Bio's stock price today?
UPB last traded at $4.61 as of Oct 7, 4:00 PM EDT, up 0.44% on the day. Prices are delayed at least 15 minutes.
When is Upstream Bio's next earnings date?
Upstream Bio is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.67.
Who is Upstream Bio's CEO?
Dr. E. Rand Sutherland M.D., M.P.H. is the chief executive officer of Upstream Bio Inc., which has about 75 employees.
What is the UPB 52-week high?
The 52-week high for UPB is $33.68 and the 52-week low is $4.50. The stock is currently 86.3% below its high.